InvestorsHub Logo
Followers 1327
Posts 248661
Boards Moderated 64
Alias Born 12/07/2009

Re: None

Thursday, 10/12/2023 12:55:00 PM

Thursday, October 12, 2023 12:55:00 PM

Post# of 118383
Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
FN Media Group LLC
Thu, October 12, 2023 at 9:00 AM EDT

PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, which are expected to offer lucrative opportunities for market expansion and flourishing opportunities. The rise in awareness and upsurge in approvals of new CAR T-cell therapies and promising advanced drugs present in pipelines are anticipated to offer remunerative opportunities for the expansion for the global CAR T-cell therapy market in the near future. Some of the benefits of CAR T-cell therapies over conventional drugs, include the destruction of cancer cells using patients' immune system, early recovery, and shortened treatment time. In addition, CAR T-cell therapy survives for a long time in the body, as they have the ability to recognize and target cancer cells even if the cancer relapses. According to a report released by Precedence Research, the global cell therapy market was valued at US$ 12 billion in 2022 and it is expected to hit US$ 83.78 billion by 2032, poised to grow at a CAGR of 21.50% during the forecast period 2023 to 2032. Further, an additional report by Allied Market Research stated the global car t-cell therapy market size was valued at $1.7 billion in 2021, and is projected to reach $6.1 billion by 2031. Active biotech and pharma companies in the markets this week include Amgen (NASDAQ:AMGN), Regen BioPharma, Inc. (OTCPK:RGBP), Gilead Sciences, Inc. (NASDAQ:GILD), GSK plc (NYSE:GSK), Incyte (NASDAQ:INCY).

Precedence Research added: “The growth of global cell therapy market is attributed to the rising incidents of chronic disorders and infections. In addition, the growing cases of diabetes are also boosting the market growth. As per the International Diabetes Federation Diabetes Altas, almost 573 million persons globally had diabetes in 2022, with the number anticipated to grow by 643 million by 2032 and 783 million by 2045. Moreover, the growing number of research studies and clinical trials are also boosting the growth of global cell therapy market. One of the key factors propelling the expansion of global cell therapy market is adoption of innovative and latest technologies. Furthermore, after the impact of COVID-19 pandemic, the market for cell therapy is growing at a rapid pace. With over 900 companies working on advanced therapeutics around the world and around 1,000 cell or gene therapy clinical studies now conducted, the cell therapy market might see a surge in number of approvals. According to industry experts, up to 60 new cell therapies could be developed in the next few years, curing around 350,000 patients in the U.S. alone.”

Regen BioPharma, Inc. Receives First Phase of Confirmatory Study - Regen BioPharma, Inc. (OTCPK:RGBP) has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic while also identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders.

The company has now received the first set of confirmatory data which demonstrates that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 were successfully created. In addition, the siRNA that is designed into the CAR T-cell was very highly expressed. Subsequent studies will determine if the expression of NR2F6 mRNA is suppressed or enhanced as a result of the high expression of siRNA.

"This is a major accomplishment in moving this model forward into therapies because in order to test whether we can genetically manipulate NR2F6 levels, we have to be able to produce a CAR T-cell where we demonstrate expression of this siRNA," says Dr. Harry Lander, Chief Scientific Consultant to the company. "We are excited to see the results on NR2F6 expression. If it is inhibited, we will focus on using these DuraCAR cells as originally envisioned - to attack solid tumors. If it is enhanced, we will begin re-tooling these cells to treat autoimmune disorders."

"We are delighted to get our first dataset from an independent CRO which shows that the CAR T-cells are doing what we expect and look forward to the next set of data which will inform us about the disease areas, whether autoimmunity or cancer, we will focus on," says Dr. David Koos, Chairman and CEO of the company. CONTINUED… Read this full press release and more news for RGBP at: https://regenbiopharmainc.com/company-news1/


Media Contact email: editor @

SOURCE Financialnewsmedia.com
Bullish
Bullish

Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!